2 completed, 1 active not recruiting, 1 recruiting. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Meningococcal Immunization: new trials by email Literature Review of Meningococcal Immunization trials Research Report on Meningococcal Immunization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine - Meningococcal Immunization, Healthy Volunteers | Recruiting | Sanofi | 706 | 2026-07-01 | 2026-07-29 | |
| Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine - Meningococcal Immunization, Healthy Volunteers | Phase 1 / Phase 2 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 750 | 2024-11-05 | 2026-01-20 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine - Meningococcal Immunization, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1328 | 2019-12-30 | 2025-02-03 |
| A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T)., Meningococcal Group C-CRM197 Conjugate Vaccine - Meningococcal Immunization | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 285 | 2006-07-25 | 2023-12-11 |
13-valent pneumococcal vaccine (1) · 4CMenB vaccine (1) · Acetaminophen (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Meningococcal Vaccines (1) · Rotavirus Vaccines (1) · Vaccines (1) · Vaxelis (1) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (1)
Sanofi Pasteur, a Sanofi Company (3) · Sanofi (1)
Brazil (1) · Czechia (1) · Denmark (1) · Finland (1) · Germany (1) · Honduras (1) · India (1) · Poland (1) · South Africa (1) · South Korea (1) · Spain (1) · United Kingdom (1)
2023 (1)